Opinion
Video
Predictors of Immunotherapy Response in Limited and Extensive SCLC
Afshin Dowlati, MD, explores which patients with small cell lung cancer experience the most significant benefit from immunotherapy in both limited and extensive stage disease, while also examining potential clinical or molecular characteristics that could serve as predictors of prolonged survival.
EP: 1.Optimizing First-Line Therapy for Limited-Stage Small Cell Lung Cancer
EP: 2.ADRIATIC Trial: Durvalumab, cCRT Timing, and Survival in LS-SCLC
EP: 3.cCRT-to-Durvalumab Interval in Limited Stage LS-SCLC
EP: 4.Examining 3-Year Update Data from the CASPIAN Trial
Now Viewing
EP: 5.Predictors of Immunotherapy Response in Limited and Extensive SCLC
EP: 6.Overcoming Immunotherapy Resistance in Small Cell Lung Cancer
EP: 7.Examining the use of PD-L1 and tTMB in the CASPIAN Trial
EP: 8.Redefining SCLC: Molecular Subtypes and Blood Biomarkers Guide Therapy
EP: 9.Navigating Later-Line Therapy Sequencing in LS-SCLC Progression
EP: 10.DELLphi-301: Platinum Chemotherapy Efficacy in SCLC Survival
EP: 11.Reviewing Ideate-Lung02: Durable Responses in Advanced SCLC
EP: 12.Examining Key Data from DAREON-8
EP: 13.Closing Thoughts and Key Takeaways on Small Cell Lung Cancer
- How do we advance the field on which patients with SCLC derive the greatest benefit from IO in both limited stage and extensive stage disease?
- Do we yet know which clinical or molecular characteristics might predict extended survival in ES-SCLC, such as platinum sensitivity or PD-L1 expression?
- For those who experience extended survival, do you continue immunotherapy and how long is that interval?
Related Videos
Related Content
